*3.8. TEM 3.8. TEM*

A representative TEM micrograph of the optimized SLN (CL10) is shown in Figure 12. The image shows the drug encapsulated in the lipid matrix. It was also observed that the lipid nanoparticles were coarsely spherical in shape and uniformly distributed. The particle size was found to be in the range of 100–200 nm. The particle size range observed in TEM image was in good agreement with the values observed in particle size analysis. A representative TEM micrograph of the optimized SLN (CL10) is shown in Figure 12. The image shows the drug encapsulated in the lipid matrix. It was also observed that the lipid nanoparticles were coarsely spherical in shape and uniformly distributed. The particle size was found to be in the range of 100–200 nm. The particle size range observed in TEM image was in good agreement with the values observed in particle size analysis.

**Figure 11.** Cumulative amount of clarithromycin permeated through the goat cornea from solid

lipid nanoparticles (CL10) and control (solution). Data represented are mean ± SD (*n* = 6).

*Pharmaceutics* **2021**, *13*, x FOR PEER REVIEW 19 of 24

**Figure 12.** Surface morphology of optimized clarithromycin solid lipid nanoparticles (CL10). Red arrow indicates the diameter of nanoparticle. **Figure 12.** Surface morphology of optimized clarithromycin solid lipid nanoparticles (CL10). Red arrow indicates the diameter of nanoparticle.
